CA2161681A1 - Derives de camptothecine hydrosolubles et leur utilisation comme agents antitumeurs - Google Patents

Derives de camptothecine hydrosolubles et leur utilisation comme agents antitumeurs

Info

Publication number
CA2161681A1
CA2161681A1 CA002161681A CA2161681A CA2161681A1 CA 2161681 A1 CA2161681 A1 CA 2161681A1 CA 002161681 A CA002161681 A CA 002161681A CA 2161681 A CA2161681 A CA 2161681A CA 2161681 A1 CA2161681 A1 CA 2161681A1
Authority
CA
Canada
Prior art keywords
camptothecin
lower alkyl
ethylenedioxy
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002161681A
Other languages
English (en)
Inventor
Jeffrey Mark Besterman
Michael Glenn Evans
Michael Joseph Luzzio
Peter Leslie Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Glaxo Wellcome Inc
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc, Glaxo Inc filed Critical Glaxo Wellcome Inc
Publication of CA2161681A1 publication Critical patent/CA2161681A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002161681A 1993-04-29 1994-04-28 Derives de camptothecine hydrosolubles et leur utilisation comme agents antitumeurs Abandoned CA2161681A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5458593A 1993-04-29 1993-04-29
US8104293A 1993-06-22 1993-06-22
US08/054,585 1993-06-22
US08/081,042 1993-06-22

Publications (1)

Publication Number Publication Date
CA2161681A1 true CA2161681A1 (fr) 1994-11-10

Family

ID=26733234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002161681A Abandoned CA2161681A1 (fr) 1993-04-29 1994-04-28 Derives de camptothecine hydrosolubles et leur utilisation comme agents antitumeurs

Country Status (10)

Country Link
EP (1) EP0696285A1 (fr)
JP (1) JPH08509740A (fr)
AP (1) AP9400638A0 (fr)
AU (1) AU6777194A (fr)
CA (1) CA2161681A1 (fr)
IL (1) IL109470A0 (fr)
IS (1) IS4152A (fr)
MY (1) MY141374A (fr)
PE (1) PE52894A1 (fr)
WO (1) WO1994025466A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
SG103322A1 (en) * 1996-10-30 2004-04-29 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418099B1 (fr) * 1989-09-15 2001-12-19 Research Triangle Institute Procédé de préparation d'analogue de la 10,11-méthylènedioxy-20(RS)camptothécine et de la 10,11-méthylènedioxy-20(S)-camptothécine
DK0540099T3 (da) * 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
CA2087898A1 (fr) * 1992-01-24 1993-07-25 Hiroshi Akimoto Composes heterocycliques condenses, leur preparation et leur utilisation

Also Published As

Publication number Publication date
IS4152A (is) 1994-10-30
WO1994025466A1 (fr) 1994-11-10
AP9400638A0 (en) 1995-10-28
MY141374A (en) 2010-04-16
IL109470A0 (en) 1994-07-31
JPH08509740A (ja) 1996-10-15
EP0696285A1 (fr) 1996-02-14
PE52894A1 (es) 1995-01-06
AU6777194A (en) 1994-11-21

Similar Documents

Publication Publication Date Title
EP0540099B1 (fr) Dérivés de camptothécine solubles dans l'eau
US5559235A (en) Water soluble camptothecin derivatives
US5342947A (en) Preparation of water soluble camptothecin derivatives
AU652728B2 (en) Camptothecin analogs as potent inhibitors of human colorectal cancer
US6100273A (en) Water soluble camptothecin derivatives
RU2380368C2 (ru) Деазапурины и их применение
US5122526A (en) Camptothecin and analogs thereof and pharmaceutical compositions and method using them
WO1990003169A1 (fr) Synthese de camptothecine et d'anlogues de celle-ci
EP0496634A1 (fr) Dérivés substitués de phenyl-1,3-dioxoloquinoléines et leur utilisation comme agents antitumoraux
US5364858A (en) Camptothecin analogs as potent inhibitors of topoisomerase I
EP0251361A1 (fr) Dérivés de la di- et tétrahydroisoquinoléine
CA2161681A1 (fr) Derives de camptothecine hydrosolubles et leur utilisation comme agents antitumeurs
AU738322B2 (en) New acronycine compounds, a process for their preparation and pharmaceutical compositions containing them
NZ520377A (en) New benzo[b]pyrano[3,2-h]acridin-7-one compounds, a process for their preparation and pharmaceutical compositions containing them
GB2280674A (en) Pyrido[3,4-b]-pyridine antitumor compounds
PL173684B1 (pl) Pochodne kamptotecyny i sposób wytwarzania pochodnych kamptofecyny
SI9300183A (sl) Vodotopni kamptotecinski derivati

Legal Events

Date Code Title Description
FZDE Discontinued